Core Viewpoint - Baiyunshan Pharmaceutical has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration, enhancing its product offerings in the male medication market [1] Summary by Categories Company Developments - Baiyunshan Pharmaceutical's subsidiary, Baiyunshan Pharmaceutical Factory, has invested approximately RMB 2.54 million and RMB 4.30 million in the research and development of Tadalafil tablets (2.5mg and 5mg) respectively [1] Market Impact - The approval of the drug registration certificate is expected to enrich the variety of male medication products offered by Baiyunshan Pharmaceutical, thereby improving its competitiveness in the male medication sector [1]